Cornell researchers found that the rare liver cancer traps immune cells in surrounding scar tissue via the CXCR4 receptor, and that the FDA approved stem cell mobilizer plerixafor reversed the trap in tumor samples and restored immunotherapy's effect.
Fibrolamellar carcinoma is the rare liver tumor that immunotherapy has not been able to reach. It strikes adolescents and young adults almost exclusively, currently has no curative option once it spreads, and has resisted most standard treatment approaches. New work from a Cornell-led team now points to a concrete reason: the tumor does not just hide from the immune system, it actively evicts T cells into the surrounding scar tissue and locks the door behind them. A drug that already sits on pharmacy shelves may be able to reverse the eviction.
The structural insight comes from a paper published in Gastroenterology by a Cornell group led by Praveen Sethupathy, professor of physiological genomics and chair of the Department of Biomedical Sciences in the College of Veterinary Medicine. The team showed that fibrolamellar tumors are saturated with a chemical signal that pulls immune T cells away from the cancer and into the fibrous stroma that wraps the tumor. The lure runs through CXCR4, a chemokine receptor best known for steering stem cells and immune cells through the body. In FLC, the same receptor acts as a one-way exit sign pointing away from the tumor.
This is the specific reason immunotherapy has struggled in FLC patients. The most-used immune drugs work by reactivating T cells that are already inside the tumor, where they can recognize and kill cancer cells. If those T cells are not inside the tumor to begin with, the treatment has nothing to work with. As the Cornell news office explained, the CXCR4 axis is essentially a structural firewall that has kept FLC immune to the standard playbook.
The second half of the finding is the practical one. AMD3100, sold under the generic name plerixafor, is an FDA-approved drug that has been used to push hematopoietic stem cells out of the bone marrow into the bloodstream for transplant collection in lymphoma and multiple myeloma patients. Its mechanism is straightforward: it blocks CXCR4, the same receptor FLC hijacks to evict T cells. When the Cornell team added plerixafor to immunotherapy in tumor samples, the trapped T cells migrated back toward the cancer and the immunotherapy's cytotoxic effect strengthened substantially. The ScienceDaily summary of the work frames the result as drug repurposing rather than drug discovery: an existing molecule retrained against a disease it was never designed to treat.
That framing is the right one. Plerixafor is not a new weapon. It is a key that happens to fit a lock FLC had been hiding. The mechanism also explains why the drug-repurposing story is genuinely new in FLC, even though CXCR4 has been studied in pancreatic, breast, and other gastrointestinal cancers. As the Fibrolamellar Cancer Foundation's plain-language summary of the Gastroenterology paper emphasizes, the contribution is the FLC-specific wiring of the CXCR4 axis, not the existence of CXCR4 as a cancer target.
The caveat is also specific. The data are pre-clinical, generated from patient-derived tumor samples rather than from a clinical trial. No FLC patients have yet been treated with the plerixafor-plus-immunotherapy combination in a published study. As Technology Networks' coverage makes clear, the next step is a clinical protocol, not a guaranteed result. For a disease with no cure, where the average patient is diagnosed after metastasis has already occurred, even a pre-clinical signal with a clean mechanistic story is worth tracking.
What to watch next: a formal trial design from the Cornell group or a collaborating oncologist, a clinical pipeline entry for plerixafor in FLC, and any signal that the CXCR4 mechanism translates from ex vivo tumor samples to a patient's actual tumor microenvironment. Until then, plerixafor is a candidate, not a cure. But for a cancer that has refused every other key offered to it, the lock is now visible.